PAX Financial Group’s Emergent Biosolutions EBS Stock Holding History

PAX Financial Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,177	Closed	-$418K	–	180
2022 Q1	$418K	Buy	+10,177	New	+$449K	0.1%	147

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAX Financial Group's EBS Position: Q2 2022 in Review

PAX Financial Group sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 10,177 shares — an estimated $418K sold.

PAX Financial Group first reported a position in EBS in Q1 2022 and held it in 1 quarter. The position peaked at $418K in Q1 2022. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

PAX Financial Group reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
PAX Financial Group sold 10,177 Emergent Biosolutions shares in Q2 2022, an estimated $418K.
PAX Financial Group first reported a position in Emergent Biosolutions in Q1 2022 and held it in 1 quarter.
PAX Financial Group's Emergent Biosolutions position peaked at $418K in Q1 2022.
232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on PAX Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.